Basic research on the biology of aging has resulted in the discovery of more than 75 interventions that extend lifespan in rodents and many more that extend lifespan in Drosophila and Caenorhabditis elegans1,2,3,4,5,6,7,8,9,10. The progression of this work to human trials was historically delayed by the misconception that interventions originally identified to extend rodent lifespan lacked a feasible translation strategy or were unattractive investment opportunities for investors and pharmaceutical companies. In the last 5 years, however, efforts to move those interventions into human experimentation have come to fruition. The biotechnology companies developing such treatments have created a new field of biopharmaceutical development: longevity biotechnology. Because longevity biotechnology represents a paradigm shift in therapeutic approach and faces unique challenges from the standpoint of clinical development, path to approval and patient population, it makes sense to define this rapidly advancing field and articulate standards that identify its bona fide constituents. The Longevity Biotechnology Association (LBA) is a non-profit organization created to foster collaboration, propose guidelines for industry, educate stakeholders and translate geroscience to prevent the diseases associated with aging and extend healthspan.
References
Liu, J. K. Nat. Prod. Bioprospect. 12, 18 (2022).
Shaposhnikov, M. V. et al. Commun. Biol. 5, 566 (2022).
Li, Z. et al. Biogerontology 22, 165–187 (2021).
Brandstädt, S., Schmeisser, K., Zarse, K. & Ristow, M. Aging (Albany NY) 5, 270–275 (2013).
Liu, W. et al. Aging (Albany NY) 12, 5300–5317 (2020).
Zhang, Y. et al. J. Gerontol. A Biol. Sci. Med. Sci. 69, 119–130 (2014).
Yang, X. et al. Aging (Albany NY) 12, 16852–16866 (2020).
Cui, X., Liang, H., Hao, C. & Jing, X. Aging (Albany NY) 13, 6625–6633 (2021).
Tian, J., Geiss, C., Zarse, K., Madreiter-Sokolowski, C. T. & Ristow, M. Aging (Albany NY) 13, 22629–22648 (2021).
Qi, Z. et al. Aging 13, 1649–1670 (2021).
Justice, J. N. et al. Cardiovasc. Endocrinol. Metab. 7, 80–83 (2018).
Macdonald-Dunlop, E. et al. Aging (Albany NY) 14, 623–659 (2022).
Ecker, S. & Beck, S. Aging (Albany NY) 11, 833–835 (2019).
Campbell, D. The State of Longevity: Annual Report 2021. https://longevity.technology/research/the-state-of-longevity-2021-report/ (LongevityTechnology, 2021).
Tosato, M., Zamboni, V., Ferrini, A. & Cesari, M. Clin. Interv. Aging 2, 401–412 (2007).
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Cell 153, 1194–1217 (2013).
Fedintsev, A. & Moskalev, A. Ageing Res. Rev. 62, 101097 (2020).
Carter, C. S. A. J. Gerontol. A Biol. Sci. Med. Sci. 76, 1891–1894 (2021).
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Cell 186, 243–278 (2023).
McLeod, C. et al. Contemp. Clin. Trials Commun. 16, 100486 (2019).
Sierra, F. et al. J. Am. Geriatr. Soc. 69, 2455–2463 (2021).
Justice, J. N. Designing the Aging Outcomes Trial Targeting Aging with MEtformin (TAME). https://www.herl.pitt.edu/symposia/metabolic-pathways/presentations/MP-Justice.pdf (Wake Forest School of Medicine, 2019).
ISSCR. ISSCR Guidelines for Stem Cell Research and Clinical Translation (International Society for Stem Cell Research, 2021)
Acknowledgements
All authors of this paper are members of the LBA. The LBA’s mission is to sponsor longevity industry and investor meetings and webcasts, connect stakeholders in the field, and provide industry and scientific education to its members. The LBA is a global non-profit, comprising a network of longevity biotechnology companies, researchers and investors. This Correspondence has been reviewed and approved by the members of the LBA. The LBA provided funding for the initial meeting of authors to discuss the ideas of the paper. No further financial support was received by the authors for the research, authorship and publication of this article.
Ethics declarations
Competing interests
N. Boekstein is director, corporate strategy at Cambrian Bio. N. Barzilai is the scientific director of the American Federation of Aging Research, on the executive board of the LBA and on the scientific advisory board of LVF and Human Edge. He is also a founder of CohBar Inc. and Life Biosciences and on the board of Sirtlab. A.B. is the CEO of HelpWear. J.B.-L. leads the longevity biotechnology company Retro Biosciences. K.F. is CEO of BioAge Labs. S.B.H. has been a paid employee and consultant of Rejuveron Life Sciences AG and a member of the board of directors of Rejuveron Senescence Therapeutics AG and SL, Rejuveron Telomere Therapeutics AG and Rejuveron Vascular Therapeutics AG. M.H. has funding, employment and personal financial interests related to the venture-backed biopharma company LyGenesis. J. Mannick is the CEO of Tornado Therapeutics. J. McLaughlin is the CEO of Life Biosciences. J. Mellon is a salaried director at Juvenescence Limited and an unpaid director at the American Federation of Aging Research. He is also on the LBA board and an unpaid trustee at the Longevity Forum and Buck Institute of Aging. E.M. is employed by BioAge Labs. N.R. is the founder and general partner of Apollo Health Ventures. Apollo Health Ventures manages and advises venture capital funds investing in longevity biotechnology companies. D.A.R. is the co-founder and CEO of a biotechnology company, Oviva Therpaeutics, that is developing therapeutics to improve ovarian function and extend healthspan in females, and also holds shares in Cambrian Bio. She serves on the scientific board of Dior Beauty, their ‘Age Reversal’ board, dedicated to advising and educating on longevity science. D.A.S. is a consultant to, inventor of patents licensed to and, in some cases, board member of and investor in Fully Aligned Co., MetroBiotech, CohBar, Life Biosciences, Immetas, Bold Capital, InsideTracker/Segterra, Zymo, Alpha Wave, EdenRoc Sciences, Galilei Biosciences, Animal Biosciences and Tally Health. He is an inventor on patent applications licensed to Bayer Crops and Merck KGaA. S.Y. is the founder of the Longevity Vision Fund. He is a board member at the American Federation of Aging Research and Innovation Board Member at the XPRIZE Foundation. R.S. holds an administrative role as the executive director at the LBA and the Academy for Health and Lifespan Research. A.Z. is the founder and CEO of Insilico Medicine, a clinical-stage generative AI and robotics biotechnology company specializing in aging research. He holds multiple granted patents on geroprotector discovery and aging clocks. J.P. is CEO of Cambrian Bio and a board member of the LBA.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Boekstein, N., Barzilai, N., Bertram, A. et al. Defining a longevity biotechnology company.
Nat Biotechnol (2023). https://doi.org/10.1038/s41587-023-01854-0
Published:
DOI: https://doi.org/10.1038/s41587-023-01854-0
